patient_id stringlengths 12 12 | record_id stringlengths 11 11 | cancer_type stringclasses 1
value | histology stringclasses 3
values | stage_at_diagnosis stringclasses 3
values | driver_mutation stringclasses 7
values | pd_l1_tps_percent int64 5 41 | tmb_mutations_per_mb float64 1.5 25 | age_at_diagnosis int64 38 90 | sex stringclasses 2
values | ecog_performance_status int64 0 4 | smoking_pack_years int64 0 111 | primary_tumor_size_cm float64 2 10 | metastatic_sites_count int64 0 11 | first_line_regimen stringclasses 6
values | overall_survival_months float64 4 83 | censored bool 2
classes | msi_status stringclasses 2
values | record_generation_timestamp stringdate 2026-03-15 05:35:56 2026-03-15 05:36:02 | synthetic_source stringclasses 1
value |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
ANODE_491517 | REC_0001401 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 27 | 5.4 | 71 | female | 1 | 15 | 4.4 | 1 | entrectinib 600 mg daily | 23.6 | false | MSS | 2026-03-15T05:35:57.189405+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_503808 | REC_0001402 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 22 | 15.9 | 76 | female | 0 | 5 | 5.9 | 6 | osimertinib 80 mg daily | 15.5 | true | MSI-H | 2026-03-15T05:35:57.189638+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_550534 | REC_0001403 | Non-small cell lung cancer | Large cell carcinoma | IVB | None (PD-L1 high) | 26 | 4.4 | 71 | male | 1 | 9 | 4.4 | 6 | pembrolizumab 200 mg q3w | 13.2 | true | MSS | 2026-03-15T05:35:57.189869+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_982088 | REC_0001404 | Non-small cell lung cancer | Large cell carcinoma | IVA | None (PD-L1 high) | 26 | 7 | 62 | male | 0 | 15 | 5.8 | 0 | pembrolizumab 200 mg q3w | 20.6 | false | MSS | 2026-03-15T05:35:57.190102+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_489816 | REC_0001405 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 24 | 8.5 | 55 | female | 0 | 6 | 5.4 | 1 | osimertinib 80 mg daily | 24.5 | true | MSS | 2026-03-15T05:35:57.190407+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_447830 | REC_0001406 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 27 | 16.9 | 60 | male | 0 | 6 | 4.3 | 6 | osimertinib 80 mg daily | 9.6 | false | MSI-H | 2026-03-15T05:35:57.190649+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_434125 | REC_0001407 | Non-small cell lung cancer | Large cell carcinoma | IVB | None (PD-L1 high) | 27 | 7.7 | 70 | female | 2 | 21 | 5.2 | 8 | pembrolizumab 200 mg q3w | 6.6 | true | MSS | 2026-03-15T05:35:57.190879+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_567594 | REC_0001408 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 19 | 12.7 | 68 | female | 0 | 15 | 4.8 | 6 | entrectinib 600 mg daily | 8.5 | false | MSS | 2026-03-15T05:35:57.191114+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_449201 | REC_0001409 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 27 | 9.4 | 48 | male | 0 | 17 | 4.5 | 8 | sotorasib 960 mg daily | 6.1 | false | MSS | 2026-03-15T05:35:57.191345+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_304370 | REC_0001410 | Non-small cell lung cancer | Large cell carcinoma | IVA | None (PD-L1 high) | 29 | 3.6 | 68 | female | 1 | 7 | 6.6 | 2 | pembrolizumab 200 mg q3w | 28.7 | false | MSS | 2026-03-15T05:35:57.191572+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_636046 | REC_0001411 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 25 | 15 | 65 | male | 1 | 17 | 4.7 | 1 | entrectinib 600 mg daily | 23.5 | false | MSI-H | 2026-03-15T05:35:57.191808+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_475483 | REC_0001412 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None (PD-L1 high) | 28 | 8.3 | 65 | female | 1 | 58 | 4.6 | 6 | pembrolizumab 200 mg q3w | 8.8 | false | MSS | 2026-03-15T05:35:57.192042+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_978430 | REC_0001413 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 31 | 12.5 | 68 | female | 0 | 12 | 6.8 | 5 | osimertinib 80 mg daily | 9.2 | true | MSS | 2026-03-15T05:35:57.192308+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_623000 | REC_0001414 | Non-small cell lung cancer | Large cell carcinoma | IVA | None (PD-L1 high) | 21 | 3.9 | 63 | male | 1 | 12 | 7 | 1 | pembrolizumab 200 mg q3w | 15.5 | true | MSS | 2026-03-15T05:35:57.192545+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_728298 | REC_0001415 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 22 | 9.9 | 65 | male | 0 | 8 | 5.2 | 5 | osimertinib 80 mg daily | 8.2 | false | MSS | 2026-03-15T05:35:57.192779+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_374246 | REC_0001416 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 27 | 3.3 | 66 | female | 1 | 55 | 6.4 | 6 | carboplatin + paclitaxel + pembrolizumab | 15.8 | false | MSS | 2026-03-15T05:35:57.193012+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_706944 | REC_0001417 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 21 | 14.5 | 72 | female | 2 | 16 | 5.3 | 3 | sotorasib 960 mg daily | 8.9 | false | MSI-H | 2026-03-15T05:35:57.193246+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_684796 | REC_0001418 | Non-small cell lung cancer | Adenocarcinoma | III | None (PD-L1 high) | 25 | 19.9 | 57 | male | 0 | 19 | 7.6 | 0 | pembrolizumab 200 mg q3w | 27.4 | true | MSI-H | 2026-03-15T05:35:57.193536+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_437129 | REC_0001419 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 19 | 11.8 | 55 | male | 0 | 17 | 6.3 | 2 | sotorasib 960 mg daily | 19.1 | true | MSI-H | 2026-03-15T05:35:57.193776+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_628614 | REC_0001420 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 22 | 19.9 | 74 | female | 1 | 19 | 3.6 | 2 | alectinib 600 mg BID | 17 | true | MSS | 2026-03-15T05:35:57.194010+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_105612 | REC_0001421 | Non-small cell lung cancer | Adenocarcinoma | IVA | None (PD-L1 high) | 21 | 7.4 | 70 | male | 1 | 16 | 6 | 0 | pembrolizumab 200 mg q3w | 11.3 | false | MSS | 2026-03-15T05:35:57.194242+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_577380 | REC_0001422 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 32 | 3.5 | 85 | female | 0 | 20 | 3.4 | 1 | carboplatin + paclitaxel + pembrolizumab | 14.4 | false | MSS | 2026-03-15T05:35:57.194472+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_289036 | REC_0001423 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 26 | 8.7 | 60 | male | 1 | 11 | 7.8 | 1 | osimertinib 80 mg daily | 10.3 | false | MSS | 2026-03-15T05:35:57.194707+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_136645 | REC_0001424 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 19 | 5.2 | 57 | female | 0 | 9 | 6.4 | 6 | entrectinib 600 mg daily | 12.8 | false | MSS | 2026-03-15T05:35:57.194938+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_162441 | REC_0001425 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 26 | 14.9 | 60 | female | 1 | 15 | 7.6 | 2 | osimertinib 80 mg daily | 7.7 | false | MSS | 2026-03-15T05:35:57.195174+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_608595 | REC_0001426 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 22 | 14.3 | 53 | male | 0 | 19 | 8.5 | 4 | osimertinib 80 mg daily | 11.1 | true | MSS | 2026-03-15T05:35:57.195405+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_220023 | REC_0001427 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 30 | 16.1 | 50 | female | 0 | 14 | 6.7 | 7 | entrectinib 600 mg daily | 13.6 | false | MSS | 2026-03-15T05:35:57.195641+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_295098 | REC_0001428 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 23 | 13.5 | 64 | female | 0 | 10 | 5.8 | 2 | entrectinib 600 mg daily | 23.2 | true | MSS | 2026-03-15T05:35:57.195875+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_969373 | REC_0001429 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 27 | 3.4 | 66 | female | 1 | 54 | 3.6 | 1 | carboplatin + paclitaxel + pembrolizumab | 19.3 | false | MSS | 2026-03-15T05:35:57.196282+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_263064 | REC_0001430 | Non-small cell lung cancer | Adenocarcinoma | III | ROS1 fusion | 17 | 17.7 | 70 | female | 2 | 17 | 6.6 | 0 | entrectinib 600 mg daily | 35.7 | true | MSI-H | 2026-03-15T05:35:57.196568+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_904847 | REC_0001431 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 24 | 20.2 | 81 | female | 1 | 13 | 5 | 2 | osimertinib 80 mg daily | 21.3 | true | MSS | 2026-03-15T05:35:57.196913+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_826686 | REC_0001432 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 23 | 8.6 | 72 | female | 1 | 52 | 5.2 | 5 | carboplatin + paclitaxel + pembrolizumab | 9 | false | MSS | 2026-03-15T05:35:57.197160+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_391859 | REC_0001433 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 28 | 13.1 | 76 | female | 1 | 22 | 7.7 | 5 | osimertinib 80 mg daily | 14.2 | true | MSI-H | 2026-03-15T05:35:57.197398+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_142393 | REC_0001434 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 26 | 13.3 | 90 | female | 1 | 20 | 6.2 | 1 | osimertinib 80 mg daily | 12.9 | true | MSI-H | 2026-03-15T05:35:57.197635+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_677639 | REC_0001435 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 31 | 5.4 | 65 | female | 1 | 35 | 5.8 | 7 | carboplatin + paclitaxel + pembrolizumab | 14.9 | true | MSS | 2026-03-15T05:35:57.197870+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_349822 | REC_0001436 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 32 | 19.8 | 70 | female | 2 | 31 | 5.4 | 3 | osimertinib 80 mg daily | 15.8 | false | MSS | 2026-03-15T05:35:57.198112+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_619796 | REC_0001437 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 25 | 13.1 | 70 | male | 2 | 10 | 4.8 | 2 | osimertinib 80 mg daily | 19.6 | false | MSS | 2026-03-15T05:35:57.198351+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_274644 | REC_0001438 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 29 | 11.6 | 61 | male | 0 | 0 | 5.5 | 4 | entrectinib 600 mg daily | 9.7 | false | MSS | 2026-03-15T05:35:57.198591+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_775295 | REC_0001439 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 18 | 16.4 | 47 | female | 0 | 11 | 3.7 | 1 | osimertinib 80 mg daily | 23.4 | true | MSI-H | 2026-03-15T05:35:57.198844+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_931568 | REC_0001440 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 25 | 18.7 | 52 | female | 0 | 24 | 5.7 | 5 | osimertinib 80 mg daily | 10.7 | true | MSS | 2026-03-15T05:35:57.199093+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_347290 | REC_0001441 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 21 | 7.7 | 69 | female | 1 | 6 | 6 | 3 | alectinib 600 mg BID | 8.6 | false | MSS | 2026-03-15T05:35:57.199343+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_799553 | REC_0001442 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 29 | 18.1 | 70 | female | 1 | 17 | 5 | 5 | osimertinib 80 mg daily | 11.6 | true | MSS | 2026-03-15T05:35:57.199594+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_437532 | REC_0001443 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 20 | 5.8 | 84 | female | 1 | 3 | 4.5 | 6 | carboplatin + paclitaxel + pembrolizumab | 10.5 | true | MSS | 2026-03-15T05:35:57.199843+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_964399 | REC_0001444 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 24 | 6.7 | 52 | male | 0 | 27 | 3.3 | 1 | carboplatin + paclitaxel + pembrolizumab | 26.6 | true | MSS | 2026-03-15T05:35:57.200267+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_434409 | REC_0001445 | Non-small cell lung cancer | Large cell carcinoma | IVA | None (PD-L1 high) | 17 | 7.3 | 79 | female | 1 | 15 | 7.7 | 2 | pembrolizumab 200 mg q3w | 23.7 | false | MSS | 2026-03-15T05:35:57.200530+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_524285 | REC_0001446 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 20 | 16.9 | 76 | male | 1 | 13 | 4.6 | 4 | alectinib 600 mg BID | 12.8 | true | MSI-H | 2026-03-15T05:35:57.200782+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_861014 | REC_0001447 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None (PD-L1 high) | 22 | 4.8 | 79 | female | 1 | 37 | 5.4 | 6 | pembrolizumab 200 mg q3w | 9.5 | false | MSS | 2026-03-15T05:35:57.201020+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_449418 | REC_0001448 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 17 | 15.7 | 82 | female | 1 | 6 | 5 | 2 | alectinib 600 mg BID | 13.9 | true | MSS | 2026-03-15T05:35:57.201257+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_645770 | REC_0001449 | Non-small cell lung cancer | Adenocarcinoma | IVB | None (PD-L1 high) | 22 | 11.5 | 75 | male | 3 | 24 | 4.6 | 7 | pembrolizumab 200 mg q3w | 15.5 | false | MSS | 2026-03-15T05:35:57.201494+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_637887 | REC_0001450 | Non-small cell lung cancer | Large cell carcinoma | IVB | None (PD-L1 high) | 23 | 4.7 | 66 | male | 1 | 19 | 5.5 | 5 | pembrolizumab 200 mg q3w | 15.2 | false | MSS | 2026-03-15T05:35:57.201729+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_737678 | REC_0001451 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 23 | 13.4 | 67 | female | 0 | 11 | 6 | 2 | alectinib 600 mg BID | 8.9 | true | MSI-H | 2026-03-15T05:35:57.201970+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_940716 | REC_0001452 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 29 | 8.6 | 61 | female | 1 | 9 | 4.7 | 3 | sotorasib 960 mg daily | 12.4 | false | MSS | 2026-03-15T05:35:57.202204+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_478406 | REC_0001453 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 16 | 12.4 | 57 | male | 0 | 14 | 6.8 | 2 | alectinib 600 mg BID | 18.3 | true | MSI-H | 2026-03-15T05:35:57.202440+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_708472 | REC_0001454 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 27 | 5.5 | 68 | female | 0 | 17 | 5.7 | 2 | entrectinib 600 mg daily | 19.7 | true | MSS | 2026-03-15T05:35:57.202673+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_300619 | REC_0001455 | Non-small cell lung cancer | Large cell carcinoma | IVA | None (PD-L1 high) | 30 | 8.2 | 66 | female | 0 | 16 | 4.7 | 1 | pembrolizumab 200 mg q3w | 24 | false | MSS | 2026-03-15T05:35:57.202903+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_666746 | REC_0001456 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 19 | 6.1 | 62 | female | 1 | 20 | 6.6 | 6 | alectinib 600 mg BID | 14.4 | true | MSS | 2026-03-15T05:35:57.203136+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_633440 | REC_0001457 | Non-small cell lung cancer | Adenocarcinoma | IVB | None (PD-L1 high) | 21 | 13.1 | 68 | female | 1 | 13 | 6.7 | 3 | pembrolizumab 200 mg q3w | 5.1 | true | MSI-H | 2026-03-15T05:35:57.203440+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_889272 | REC_0001458 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 22 | 18.2 | 58 | female | 1 | 17 | 5 | 6 | entrectinib 600 mg daily | 13.8 | false | MSS | 2026-03-15T05:35:57.203684+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_321122 | REC_0001459 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 29 | 10.3 | 64 | female | 0 | 18 | 5.3 | 1 | osimertinib 80 mg daily | 9.3 | false | MSS | 2026-03-15T05:35:57.203938+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_664402 | REC_0001460 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 17 | 18.4 | 63 | male | 1 | 2 | 7.9 | 4 | osimertinib 80 mg daily | 13.6 | true | MSI-H | 2026-03-15T05:35:57.204247+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_326333 | REC_0001461 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 32 | 14.1 | 71 | female | 1 | 10 | 5.1 | 5 | sotorasib 960 mg daily | 10.8 | false | MSI-H | 2026-03-15T05:35:57.204518+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_549325 | REC_0001462 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 28 | 7 | 62 | female | 0 | 13 | 7.2 | 3 | alectinib 600 mg BID | 15.7 | true | MSS | 2026-03-15T05:35:57.204782+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_581976 | REC_0001463 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 20 | 9.8 | 67 | female | 0 | 15 | 2.4 | 5 | alectinib 600 mg BID | 12.3 | true | MSS | 2026-03-15T05:35:57.205033+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_106121 | REC_0001464 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 26 | 11.3 | 68 | female | 0 | 12 | 5.9 | 2 | sotorasib 960 mg daily | 20.7 | false | MSI-H | 2026-03-15T05:35:57.205285+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_999024 | REC_0001465 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 17 | 14.1 | 71 | female | 1 | 19 | 4.4 | 5 | osimertinib 80 mg daily | 18.6 | false | MSS | 2026-03-15T05:35:57.205545+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_761828 | REC_0001466 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 25 | 3.5 | 56 | male | 0 | 51 | 3.5 | 5 | carboplatin + paclitaxel + pembrolizumab | 12.7 | false | MSS | 2026-03-15T05:35:57.205804+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_344520 | REC_0001467 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 25 | 10.6 | 67 | male | 0 | 14 | 6.7 | 4 | osimertinib 80 mg daily | 11.9 | true | MSS | 2026-03-15T05:35:57.206057+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_459624 | REC_0001468 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 20 | 12.8 | 69 | female | 0 | 16 | 3.2 | 1 | entrectinib 600 mg daily | 9.7 | false | MSS | 2026-03-15T05:35:57.206316+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_926277 | REC_0001469 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 26 | 17.9 | 63 | male | 0 | 9 | 6.1 | 1 | alectinib 600 mg BID | 17.3 | false | MSI-H | 2026-03-15T05:35:57.206566+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_635308 | REC_0001470 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 28 | 16.8 | 69 | female | 1 | 15 | 4.4 | 9 | alectinib 600 mg BID | 17.5 | true | MSS | 2026-03-15T05:35:57.206932+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_325628 | REC_0001471 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 26 | 13.2 | 62 | female | 1 | 20 | 6.5 | 1 | sotorasib 960 mg daily | 25.9 | true | MSS | 2026-03-15T05:35:57.207184+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_151091 | REC_0001472 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 22 | 11.9 | 75 | female | 1 | 15 | 5.2 | 4 | sotorasib 960 mg daily | 12.8 | false | MSS | 2026-03-15T05:35:57.207416+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_125566 | REC_0001473 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 25 | 20.7 | 62 | female | 1 | 12 | 6.9 | 4 | osimertinib 80 mg daily | 12.8 | false | MSI-H | 2026-03-15T05:35:57.207654+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_871580 | REC_0001474 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 26 | 13.9 | 70 | female | 1 | 23 | 5.6 | 4 | sotorasib 960 mg daily | 12.1 | false | MSS | 2026-03-15T05:35:57.207886+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_169252 | REC_0001475 | Non-small cell lung cancer | Large cell carcinoma | IVB | None (PD-L1 high) | 26 | 9.2 | 56 | male | 1 | 15 | 4.4 | 5 | pembrolizumab 200 mg q3w | 15.5 | true | MSS | 2026-03-15T05:35:57.208274+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_721651 | REC_0001476 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 28 | 10.2 | 79 | female | 0 | 17 | 3.9 | 5 | osimertinib 80 mg daily | 4 | false | MSS | 2026-03-15T05:35:57.208536+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_973912 | REC_0001477 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None (PD-L1 high) | 26 | 11 | 74 | female | 1 | 5 | 5.9 | 8 | pembrolizumab 200 mg q3w | 9.3 | false | MSS | 2026-03-15T05:35:57.208771+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_408109 | REC_0001478 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 18 | 11 | 72 | female | 1 | 15 | 3.5 | 5 | alectinib 600 mg BID | 9.3 | true | MSI-H | 2026-03-15T05:35:57.209010+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_195940 | REC_0001479 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 18 | 10.4 | 82 | female | 1 | 22 | 6.1 | 6 | sotorasib 960 mg daily | 14.2 | true | MSI-H | 2026-03-15T05:35:57.209247+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_675595 | REC_0001480 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 21 | 13.6 | 62 | female | 1 | 19 | 6.9 | 2 | sotorasib 960 mg daily | 13.9 | false | MSI-H | 2026-03-15T05:35:57.209484+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_723882 | REC_0001481 | Non-small cell lung cancer | Large cell carcinoma | IVB | None (PD-L1 high) | 22 | 8.5 | 62 | male | 0 | 18 | 4.9 | 7 | pembrolizumab 200 mg q3w | 9.6 | false | MSS | 2026-03-15T05:35:57.209718+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_393191 | REC_0001482 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 21 | 11.4 | 73 | male | 2 | 15 | 4.8 | 1 | entrectinib 600 mg daily | 15.7 | true | MSS | 2026-03-15T05:35:57.209952+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_970762 | REC_0001483 | Non-small cell lung cancer | Adenocarcinoma | III | EGFR L858R | 35 | 13.8 | 65 | female | 1 | 13 | 5.6 | 0 | osimertinib 80 mg daily | 43.4 | true | MSI-H | 2026-03-15T05:35:57.210261+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_986474 | REC_0001484 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 28 | 15.3 | 63 | male | 0 | 19 | 5.8 | 4 | osimertinib 80 mg daily | 11.5 | true | MSI-H | 2026-03-15T05:35:57.210503+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_594134 | REC_0001485 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 14 | 11 | 82 | female | 1 | 18 | 5.4 | 1 | entrectinib 600 mg daily | 8.3 | true | MSI-H | 2026-03-15T05:35:57.210742+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_450043 | REC_0001486 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 19 | 14.4 | 75 | female | 2 | 17 | 4.4 | 7 | osimertinib 80 mg daily | 7 | false | MSS | 2026-03-15T05:35:57.210974+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_146313 | REC_0001487 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 26 | 2.2 | 72 | female | 2 | 8 | 7.7 | 1 | osimertinib 80 mg daily | 22.4 | true | MSS | 2026-03-15T05:35:57.211203+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_981688 | REC_0001488 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 29 | 15.9 | 71 | female | 2 | 21 | 5.2 | 5 | sotorasib 960 mg daily | 11.9 | true | MSS | 2026-03-15T05:35:57.211437+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_207530 | REC_0001489 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 25 | 14.1 | 64 | female | 1 | 22 | 6.8 | 7 | osimertinib 80 mg daily | 7.3 | true | MSS | 2026-03-15T05:35:57.211672+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_328245 | REC_0001490 | Non-small cell lung cancer | Adenocarcinoma | III | EGFR L858R | 25 | 9.3 | 79 | female | 2 | 17 | 3.8 | 0 | osimertinib 80 mg daily | 28.6 | true | MSS | 2026-03-15T05:35:57.211904+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_874025 | REC_0001491 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 31 | 12.5 | 84 | female | 2 | 3 | 4.4 | 6 | sotorasib 960 mg daily | 17.2 | true | MSS | 2026-03-15T05:35:57.212197+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_210115 | REC_0001492 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 20 | 10.8 | 62 | male | 0 | 14 | 4.2 | 1 | alectinib 600 mg BID | 16.7 | false | MSI-H | 2026-03-15T05:35:57.212447+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_295204 | REC_0001493 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 23 | 4 | 61 | female | 1 | 60 | 6 | 2 | carboplatin + paclitaxel + pembrolizumab | 17.1 | true | MSS | 2026-03-15T05:35:57.212684+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_707211 | REC_0001494 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 24 | 14 | 69 | female | 1 | 13 | 8.2 | 2 | entrectinib 600 mg daily | 17 | true | MSS | 2026-03-15T05:35:57.212918+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_776075 | REC_0001495 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 19 | 6.2 | 57 | female | 0 | 20 | 3.3 | 2 | entrectinib 600 mg daily | 18.3 | false | MSS | 2026-03-15T05:35:57.213151+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_865280 | REC_0001496 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 28 | 19.2 | 69 | female | 0 | 7 | 6.2 | 5 | alectinib 600 mg BID | 7.2 | true | MSS | 2026-03-15T05:35:57.213432+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_417611 | REC_0001497 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 24 | 6.2 | 90 | female | 2 | 24 | 5.5 | 5 | entrectinib 600 mg daily | 9.8 | false | MSS | 2026-03-15T05:35:57.213663+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_719483 | REC_0001498 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 23 | 9.2 | 52 | male | 0 | 18 | 7.2 | 5 | entrectinib 600 mg daily | 15.2 | true | MSS | 2026-03-15T05:35:57.213896+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_184789 | REC_0001499 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 22 | 11.2 | 73 | female | 0 | 21 | 6.4 | 6 | sotorasib 960 mg daily | 8.7 | false | MSI-H | 2026-03-15T05:35:57.214128+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_515288 | REC_0001500 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 25 | 12.2 | 59 | male | 0 | 24 | 7.3 | 4 | alectinib 600 mg BID | 7.9 | false | MSI-H | 2026-03-15T05:35:57.214363+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.